Clinical trial · people
Teriparatide then denosumab: 21.9% spine bone density gain
Checked against the paper Clinical trialPublished by PepVault
The takeaway
For people using teriparatide, this study shows that following it with denosumab kept raising bone density in premenopausal women with severe osteoporosis.
- Kind
- Clinical trial
- Studied in
- People
- Number studied
- 32
- Published
- 2022
- Journal
- J Clin Endocrinol Metab
What they tested
The team wanted to see what 12 and 24 months of denosumab does to bone in premenopausal women with idiopathic osteoporosis (bone loss with no known cause) who had just finished 24 months of teriparatide.
How the study was done
A preplanned phase 2B extension study with no comparison group. Women who had completed teriparatide received the trial's denosumab schedule of 60 mg every 6 months for 24 months; 32 took it for 12 months and 29 for 24 months.

What they found
On denosumab, bone mineral density (BMD) at the lumbar spine rose 5.2% at 12 months and 6.9% at 24 months. The total hip rose 2.9% and 4.6%, and the femoral neck rose 3.0% and 4.7%. Across the full 24 months of teriparatide plus 24 months of denosumab, BMD rose 21.9% at the lumbar spine, 9.8% at the total hip and 9.5% at the femoral neck, all statistically significant. Trabecular bone score, a score of the spongy inner bone's structure, rose 5.8%; blood markers of bone turnover fell 75% to 85% by 3 months and stayed low through 12 months, and denosumab was generally well tolerated.
What it doesn’t show
This was a small extension study with no control group, so it can't show how this sequence compares with teriparatide alone or another follow-up drug. It included only premenopausal women with severe idiopathic osteoporosis, and it measured bone density and markers rather than fracture rates.
The paper
Shane et al. Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis. J Clin Endocrinol Metab. 2022.
The compound
More studies on Teriparatide
- Abaloparatide, teriparatide beat other drugs on spine BMD in menMeta-analysis · people · 2025
- Teriparatide cut fracture risk vs bisphosphonates (RR 0.61)Meta-analysis · people · 2024
- Abaloparatide: larger hip BMD gains than teriparatide at 24 weeksMeta-analysis · people · 2023
- Teriparatide: more bony union at 6 months than zoledronate after PLIFRandomized trial · people · 2022
- Teriparatide: 45.4% of jaw osteonecrosis lesions resolved by 52 weeksRandomized trial · people · 2020
- Teriparatide: fewer new vertebral fractures than risedronate in VERORandomized trial · people · 2018
- Every study on Teriparatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.